: several studies included a small number of patients [10] [11] [12] [13] 16, 17, 19, 25 or patients with posterior circulation occlusion 18, 21, 23, 25 ; in some of Background and Purpose-Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT) improves functional outcome in patients with ischemic stroke related to proximal-vessel occlusion in the anterior circulation. Whether MT alone is as effective as IVT/MT remains controversial. We aimed at evaluating the influence of IVT in patients with large anterior circulation artery occlusion treated with MT. Methods-We did a prospective observational cohort study in patients with stroke related to large anterior circulation artery occlusion treated by MT who were admitted to Lille University Hospital, Lille, France. We evaluated the influence of IVT on favorable functional outcome (defined as a modified Rankin Scale score 0-2 or similar to the prestroke modified Rankin Scale) and on mortality at month 3. Between-group comparisons in outcomes were adjusted for prespecified confoundors by using a propensity score-adjusted approach. 
B
esides intravenous thrombolysis (IVT), mechanical thrombectomy (MT) improves functional outcome in patients with ischemic stroke related to proximal vessel occlusion in the anterior circulation. [1] [2] [3] [4] [5] [6] [7] MT was proposed as an adjunctive therapy to IVT, [4] [5] [6] [7] but in 3 of the major randomized controls trials (RCTs), patients who were not eligible to IVT were also included. [1] [2] [3] Interestingly, the effect of MT was similar in patients treated with MT alone compared with those treated with IVT and MT. This suggests that MT alone could be an option. Avoiding prior IVT could indeed reduce the delay between stroke onset and initiation of MT and, therefore, reduce the time to recanalization which has been shown to be an important predictor of good outcome. 8, 9 It could also reduce risks of both intracerebral and extracerebral hemorrhages. 10 However, it has also been suggested that previous administration of intravenous r-tPA (recombinant tissue-type plasminogen activator) could facilitate MT, with a higher rate of successful recanalization, 11 shorter procedures, 12 and shorter times to recanalization. 13 Moreover, IVT could help dissolving distal thrombi not accessible with MT, 14 which could improve outcome. 15 To date, no RCT has compared MT to IVT/MT in stroke related to large artery occlusion in the anterior circulation. Even if some studies have focused on safety and efficacy of MT alone compared with IVT/MT, results remain conflicting
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June 2018 these studies, not all patients had received a full dose of intravenous r-tPA before endovascular treatment, 10, 13, 21 which could have decreased the efficacy of IVT. In the 2 largest studies, 23, 24 MT alone was found to be as effective as IVT/MT, which is in accordance with the results of the pooled analysis from STAR (Solitaire Flow Restoration Thrombectomy for Acute Revascularization) and SWIFT (Solitaire With the Intention for Thrombectomy) studies. 26 However, a recent meta-analysis from the 7 published RCTs has suggested that IVT and endovascular procedure were complementary, 27 with a lower rate of 90-day death/severe dependency in the IVT/MT group.
The aim of our study was to evaluate the influence of IVT in patients treated with MT for acute ischemic stroke related to an occlusion of a proximal artery in the anterior circulation, by comparing outcomes between patients treated by bridging therapy (IVT/MT group) or MT alone (MT group).
Patients and Methods
In this prospective study, we included patients from the Lille reperfusion registry, which is an ongoing observational registry. The data that support the findings of this study are available from the corresponding author on reasonable request. We included all consecutive patients (no upper limit) and admitted to Lille University Hospital (Lille, France) with an ischemic stroke treated by MT, with or without prior IVT. We excluded patients with basilar artery occlusion and patients with stroke related to an anterior circulation occlusion who did not undergo MT because of recanalization, either spontaneously or after intravenous r-tPA. For the purpose of this study, we included patients with stroke related to a proximal occlusion in the anterior circulation and treated by MT between January 1, 2012, and December 31, 2016. The organization of this stroke unit has previously been reported. 28 
Eligibility Criteria
Eligibility criteria for intravenous thrombolysis were those of ECASS-2 study (European Cooperative Acute Stroke Study) with a time window set at 4.5 hours. 29 Age >80 years was not an exclusion criterion. [29] [30] [31] Patients with unknown time of stroke onset were treated if they had a diffusion-weighted imaging/fluid attenuated inversion recovery mismatch on magnetic resonance imaging (MRI) performed at admission.
Eligibility criteria for endovascular treatment were age beyond 18 years, National Institutes of Health Stroke Scale (NIHSS) score ≥2, presence of large vessel occlusion in anterior circulation on noninvasive vascular imaging, and possibility to start endovascular treatment within 8 hours after stroke onset. As for intravenous thrombolysis, patients with unknown time of onset were treated if they had a diffusion-weighted imaging/fluid-attenuated inversion recovery mismatch on MRI performed at admission. Endovascular treatment was proposed after start of intravenous r-tPA in patients eligible for IVT and as a first-line treatment in patients with contraindication to IVT (direct MT).
Treatments
All eligible patients received a full dose of intravenous r-tPA according to the recommendations of the European Stroke Organisation 30 (0.9 mg/kg, maximum 90 mg; 10% bolus followed by a 60-minute infusion). Treatment with intravenous r-tPA was administered as soon as possible either at the Lille Hospital in patients directly admitted in our institution or before transfer in patients referred from remote hospitals.
The endovascular procedure was initiated as soon as possible and consisted of MT with aspiration catheters alone, stent-retrievers alone, or both, depending on occlusion type and operators choice. The procedure was performed by one of the trained neurointerventionalists of the Lille University Hospital, under conscious sedation, by transfemoral approach.
Imaging
At admission, the first-line imaging was MRI with T2 fluidattenuated inversion recovery, gradient echo T2*, diffusion b1000 with apparent diffusion coefficient mapping, and 3-dimensional time of flight MR angiography sequences. In case of contraindication for MRI, patients underwent brain computed tomography (CT) and CT angiography. For patients referred from remote hospitals, a second noninvasive imaging was performed at admission at the Lille Hospital, in case of significant clinical change (improvement or worsening) as judged by the neurologist in charge of the patient. All patients underwent follow-up MRI with contrast-enhanced MR angiography (or CT-CT angiography) 24 hours after treatment or earlier in case of clinical worsening.
Data Collection

Clinical Data
We prospectively collected the following data: demographic characteristics (age, sex), main vascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, previous or current smoking), prior vascular events (myocardial infarction, transient ischemic attack, or stroke), previous or current atrial fibrillation, antithrombotic medication received before stroke. We recorded the modified Rankin Scale score 32 before stroke and whether the patient was directly admitted or not in the Lille University hospital. Blood pressure and serum glucose level before MT were recorded. 28 The clinical severity was assessed using the NIHSS score 33 immediately before endovascular treatment and 24 hours after treatment. Early neurological improvement was defined by an improvement of >8 points of the NIHSS score or a NIHSS score at 0 after 24 hours.
We recorded the time of symptom onset, needle time (start of intravenous r-tPA infusion), and time of groin puncture (estimated by the time of pretreatment cerebral angiography). For patients with unknown stroke onset time, we recorded the time when the patient was last seen normal. When the time of onset was unknown, the onset-toendovascular treatment time was considered as the delay between the last time the patient was known normal and time of groin puncture if it was ≤8 hours. When the delay was potentially of >8 hours and the decision of treatment given on the basis of a diffusion/fluid-attenuated inversion recovery mismatch, we considered the delay as being of 8 hours. The cause of ischemic stroke was determined at discharge according to TOAST criteria (Trial of ORG 10172 in Acute Stroke Treatment). 34 The occurrence of symptomatic intracerebral hemorrhage was defined according to ECASS-2 criteria.
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Radiological Data
The extent of ischemic lesion was estimated using the Alberta Stroke Program Early CT Score (ASPECTS) 35 determined on the last cerebral imaging (MRI or CT scan) performed before the endovascular procedure, corresponding to the first imaging performed in emergency, and for some patients (especially those referred from other hospitals) to a second imaging performed just before MT. Intracerebral hemorrhages were classified radiologically on imaging performed at 24 hours using ECASS trials criteria 29, 36, 37 as hemorrhagic infarction and parenchymal hematoma. The site of occlusion was determined on initial digital subtraction angiography: middle cerebral artery (MCA-M1 or M2), associated internal carotid artery (ICA) and MCA occlusion (terminus ICA occlusion or Tandem occlusion), and isolated extracranial ICA occlusion. The degree of recanalization after MT was evaluated using the modified Thrombolysis in Cerebral Infarction scale (mTICI). 38 Successful recanalization was defined as mTICI score 2b or 3. Radiological images (MRI, CT, digital subtraction angiography) were analyzed by a neuroradiologist blinded to clinical data. The type of device was recorded: aspiration alone, stent-retrievers alone, both or none in case of impossibility to reach the site of occlusion. The delay between the last imaging before thrombectomy and groin puncture (picture to puncture time) was calculated. The duration of the procedure was measured by the time elapsed between the pretreatment and last cerebral angiograms.
Outcome
The primary study outcome was the percentage of patients who achieved a favorable 90-day outcome, defined as a modified Rankin Scale score of 0 to 2 or similar to the prestroke Rankin Scale score. 31 Secondary outcomes included clinical outcomes (excellent 90-day outcome defined as a modified Rankin Scale score of 0-1 or similar to the prestroke Rankin Scale score, 90-day all-cause mortality, parenchymal hematoma, symptomatic intracerebral hemorrhage, and early neurological improvement) and angiographic outcomes (successful reperfusion defined by mTICI 2b/3, complete reperfusion defined by mTICI 3).
Statistical Analysis
Quantitative variables were expressed as mean (SD) in case of normal distribution or median (interquartile range) otherwise. Categorical variables were expressed as number (percentage). Normality of distributions was assessed using histograms and Shapiro-Wilk test.
Bivariate comparisons between the 2 study groups (direct MT versus IVT/MT) were made using Student t test for Gaussian continuous variables, Mann-Whitney U test for nonGaussian continuous and ordinal categorical variables, and χ 2 test or Fisher exact test when appropriate for categorical variables, as appropriate. Differences in outcomes (successful reperfusion, complete reperfusion, favorable and excellent outcomes, early neurologic improvement, 90-day mortality, parenchymal hematoma, and symptomatic intracerebral hemorrhage) between the 2 study groups were expressed as relative risks (RRs) with 95% confidence intervals (CIs) using direct MT group as reference. Between-group comparisons in outcomes were adjusted for prespecified potential confounding factors (age, hypertension, diabetes mellitus, hypercholesterolemia, smoking, previous or current atrial fibrillation, previous transient ischemic attack or stroke, previous antithrombotic medication, unknown onset stroke, admission NIHSS and ASPECTS scores, onset to puncture time, and site of occlusion) using a propensity score-adjusted approach. Propensity score was calculated using a multivariable logistic regression model with treatment group as dependent variable and prespecified confounding factors as covariates. Propensity score-adjusted RRs were calculated using a generalized estimating equations (modified Poisson regression analysis-treated propensity score as covariate). 39 As a sensitivity analysis, patients from direct MT group were matched 1:1 to patients from IVT+MT group according to propensity score using the greedy nearest neighbor matching algorithm with a caliper width of 0.2 SD of logit of propensity score. 40, 41 To evaluate bias reduction using the propensity score-matching method, absolute standardized differences were calculated, and an absolute standardized difference of >10% indicated a meaningful imbalance in the baseline covariate. 42 Matched RRs were calculated using generalized estimating equation models take account matched design.
Finally, we investigated the heterogeneity in treatment differences on favorable outcome and parenchymal hematoma rate according to the following key subgroups: site of occlusion (isolated MCA versus ICA or tandem MCA), reperfusion status at end of procedure (mTICI 0/1/2a versus mTICI 2b versus mTICI 3), age (<80 versus ≥80 years), time of onset known or unknown, and transfer from other hospital. Heterogeneity in treatment effect size across subgroups was tested by introducing the corresponding multiplicative term into generalized estimating equation model. Statistical testing was conducted at the 2-tailed level of 0.05. Data were analyzed using the SAS software version 9.4 (SAS Institute, Cary, NC).
Ethics
The ethical committee (Comité de protection des personnes Nord Ouest IV) classified the study as observational on March 9, 2010, and the committee protecting personal informations of the patient approved the study by December 21, 2010 (n° 10.677). The patient and their relatives gave an informed consent to participate.
Results
Population
From January 1, 2012, to December 31, 2016, 485 consecutive patients with an ischemic stroke associated with an acute ICA or MCA occlusion were treated by MT (Figure 1 ). Of these, 348 patients (72%) received IVT before MT (IVT/MT group) and Table 2 shows the baseline characteristics in the 2 groups. There were several meaningful differences in medical history between groups: the proportion of patients with arterial hypertension, previous myocardial infarction, previous or current atrial fibrillation, previous transient ischemic attack or stroke, previous antithrombotic medication, and prestroke modified Rankin Scale score >2 were lower in the IVT/MT group. The IVT/MT group had a higher rate of patients referred from remote hospitals, less cardioembolic strokes, and a larger picture to puncture time. As shown in Table I and Figure I in the online-only Data Supplement, between-group differences in prespecified confounding factors were reduced in propensity-matched cohort with a maximum absolute difference of 16% for unknown onset time of stroke.
Outcome and Therapeutic Approach
Clinical Outcomes
Favorable outcome (primary outcome) was achieved in 21.9% of patients (n=30) in the direct MT group and in 35.3% (n=123) in the IVT/MT group, with an unadjusted RR of 1.61 (95% CI, 1.14-2.28). This difference remained significant in the adjusted propensity-adjusted analysis (adjusted RR, 1.76; 95% CI, 1.23-2.55). Patients treated by combined IVT and MT were also more likely to have early neurological improvement and an excellent outcome in unadjusted and adjusted analyses (Table 3) .
Conversely, all-cause mortality within 90 days occurred less frequently in IVT/MT group (14.4%; n=50) than in direct MT group (32.1%; n=44; unadjusted RR, 0.45; 95% CI, 0.31-0.64). This difference in favor of IVT/MT group remained significant in propensity score-adjusted cohort (adjusted RR, 0.46; 95% CI, 0.31-0.70). There is no difference between the 2 groups on hemorrhagic complications (Table 3) .
Successful reperfusion was more frequent in the IVT/ MT group (75.0% versus 59.9%, respectively; unadjusted RR, 1.25; 95% CI, 1.08-1.46). This difference remained unchanged in propensity score-adjusted analysis (adjusted RR, 1.30; 95% CI, 1.11-1.53). However, when only complete reperfusion was considered (TICI 3), no difference between the 2 groups was found in both unadjusted and adjusted analyses (P=0.75 and P=0.72, respectively).
Propensity score-matched sensitivity analysis yielded similar findings (Table II in 
Subgroup Analysis
When the analysis in primary outcome (favorable) was stratified according to key subgroups, we found no significant heterogeneity in the treatment effect size (Figure 2 ). There was no significant heterogeneity in the treatment difference on parenchymal hematoma between subgroups ( Figure 3 ).
Discussion
Our study has shown that in patients with ischemic stroke related to a proximal occlusion in the anterior circulation, IVT/ MT was associated with a better outcome and a lower mortality Values are expressed as n (%) unless otherwise indicated. AF indicates atrial fibrillation; ASPECTS, Alberta Stroke Program Early CT Score; BP, blood pressure; IQR, interquartile range; IVT, intravenous thrombolysis; MCA, middle cerebral artery; MI, myocardial infarction; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
*n=2missing values. †n=1 missing value.
rate and a higher rate of recanalization, as compared with direct MT alone, without differences for the occurrence of symptomatic intracerebral hemorrhage. This result was independent of age, site of occlusion, and recanalization status. It was observed in patients with wake-up stroke, as well as in patients with a known onset time, and in patients referred from other hospitals, as well as in patients directly admitted in our institution. Our results are in accordance with the recent meta-analysis performed by Tsivgoulis et al, 27 suggesting a better outcome in patients treated by IVT/MT but not with 2 previous studies conducted in large groups of patients with ischemic stroke involving anterior circulation. 23, 24 In one of them, 23 the time from stroke onset to groin puncture was, however, much longer in patients treated by IVT/MT compared with patients treated by MT alone, with ≈50 minutes lost when patients were treated with IVT. This was not the case in our study, suggesting that in well trained centers, the administration of intravenous r-tPA may not delay MT. In the other study, 24 ≈10% of patients were *Propensity score calculated from prespecified confounding factors (age, hypertension, diabetes mellitus, hypercholesterolemia, smoking, previous or current AF, previous TIA or stroke, previous antithrombotic medication, unknown onset stroke, NIHSS, ASPECTS, onset to puncture time and isolate MCA occlusion).
†Prespecified primary outcome defined as a 90-day mRS score of 0 to 2 or similar to prestroke mRS score. ‡Ninety-day mRS of 0 to 1, or equal to prestroke Rankin Scale score. §ENI: NIHSS score 0 at 24 hours or a decrease of ≥8points in NIHSS score at 24 hours. lost to follow-up, and possible imbalance between treatment groups was not evaluated. In our study, no patient was lost to follow-up. Some other data have suggested that intravenous r-tPA before MT might improve outcome. Guedin et al, 18 in a population of 68 patients with MCA occlusion, reported higher rates of early neurological improvement and favorable outcome at month 3 in patients treated by IVT/MT compared with MT alone (68% versus 52%, respectively), but the difference was not significant, which might be explained by the small sample size. 18 Pfefferkorn et al 12 reported that patients treated by IVT/MT were more likely to be functionally independent at month 3. Kass-Hout et al 13 reported a lower rate of death at month 3 in patients treated by IVT/MT (19% versus 29%), but the difference was not significant. Our study is, to our knowledge, the first to have found improvement in both functional and vital outcomes patients treated by IVT/ MT compared with MT alone. This better outcome observed after IVT/MT is probably mainly explained by the higher rate of successful recanalization achieved, and it was observed in all subgroups of patients with a similar treatment effect size.
The strengths of our study were the large sample size, prospective collection of data, with few missing data, and no patient lost to follow-up. The characteristics of our patients and the outcome at 3 months were similar to those reported in the recent RCTs on MT, [1] [2] [3] [4] [5] [6] [7] suggesting a good external validity of our findings. The proportion of patients with a favorable outcome in the entire cohort was 31.5%, which probably not only reflects the lack of selection on sophisticated imaging criteria but also the lack of selection on age and comorbidities. This result is similar to what has been reported in MR CLEAN trial (which was the first positive trial), where 33% of patients treated with MT had a favorable outcome. Actually, our selection criteria for MT were close to those of MR CLEAN (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands).
Concerning imaging data, we have used ASPECTS to evaluate the extension of the ischemic lesion although it could be better to use lesion volume as the volume of infarct probably predicts better the outcome than ASPECTS does. This has, however, never been demonstrated, and ASPECTS has been used in most RCTs that have evaluated the efficacy of MT. [1] [2] [3] 5, 6 The main limitation is the monocentric design and the need for validation in other cohorts. Another issue is that the present findings are derived from observational analyses that are subject to well-known limitations. The first limitation is the potential for confounding by measured or unmeasured variables, which cannot be ruled out, even after propensity score matching/adjustment because propensity matching cannot counteract baseline imbalances between groups. Moreover, in our institution, MT alone is limited to patients with contraindication for intravenous r-tPA. For that reason, treatment groups are not directly comparable because patients with contraindication for intravenous r-tPA have usually more comorbidities. Although the propensity analysis minimized bias, we cannot exclude that a part of the findings is because of imbalance between groups.
However, the rate of successful recanalization, which has a major influence on outcome, 8 was much higher in IVT/MT group. This is in accordance with previous data that have suggested that administration of intravenous r-tPA could facilitate MT with a higher rate of recanalization. 11, 16, 18 There was a slight difference in picture to groin time, but this difference was of only 8 minutes and nonsignificant. This difference may be too small to consider that intravenous r-tPA has delayed MT. All patients received the bolus and the full dose of r-tPA, and the infusion was not stopped, even in case of successful recanalization, because it has been suggested that IVT could help dissolving distal thrombi not accessible to MT.
In our institution, the decision to perform MT is, as it was the case in MR CLEAN trial, not based on core volume and 
Stroke
June 2018 mismatch criteria. Because our decisions are not influenced by these data, we did not perform perfusion imaging in our patients, in an attempt to reduce delays. Therefore, we cannot exclude an imbalance between groups concerning these variables. While awaiting for ongoing RCTs results (SWIFT DIRECT [Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke]; NCT03192332), our findings encourage not to avoid IVT before MT, when possible, in patients with acute brain ischemia related to large artery occlusion in the anterior circulation.
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